Thrice‐Daily Blood Pressure Readings on Sotalol in the Treatment of Hypertension: Once‐ Versus Twice‐Daily Regimen
- 9 August 1979
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 19 (8-9) , 533-539
- https://doi.org/10.1002/j.1552-4604.1979.tb02519.x
Abstract
Thirty patients with mild to severe essential hypertension satisfactorily controlled by twice-daily sotalol therapy entered a double-blind, crossover study comparing the efficacy, tolerability and safety of their usual twice-daily sotalol administration with the same dosage given once daily. Each double-blind period extended 8 wk, during the last week of which blood pressure and pulse rate were recorded by a nurse 3 times daily on alternate days during in the patients'' usual living conditions. Plasma sotalol concentration was measured before the morning dosage of sotalol. No statistically significant differences in the parameters were found between once- and twice-daily sotalol administration using sotalol in daily dosages from 80-320 mg. All patients concluded the trial, and no increase in side effects was noted during the once-daily period.This publication has 19 references indexed in Scilit:
- Letter: Once-daily treatment of hypertension.BMJ, 1976
- Human Pharmacokinetics of SotalolActa Pharmacologica et Toxicologica, 1976
- Once-daily dosing with Atenolol in patients with mild or moderate hypertension.BMJ, 1976
- Studies of the absorption and removal of propranolol in hypertensive patients during therapy.Circulation, 1975
- RANDOMISED CLINICAL TRIAL OF STRATEGIES FOR IMPROVING MEDICATION COMPLIANCE IN PRIMARY HYPERTENSIONThe Lancet, 1975
- HEART-RATE CHANGES DURING MOVEMENT OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1974
- Pharmacokinetic Properties of the ??-Adrenergic Receptor Blocking DrugsDrugs, 1974
- Letter: Suicidal attempts with beta-adrenoceptor blocking agents.BMJ, 1973
- Sotalol-Induced Beta Blockade in Cardiac PatientsCirculation, 1970
- Sotalol: A new, safe beta adrenergic receptor blocking agent∗The American Journal of Cardiology, 1968